HUMA - Rasio utang marang kapitalisasi buku Humacyte Inc

This daily price chart for Humacyte, Inc. (HUMA) reflects the dynamics of a company whose operations are constrained by risks associated with Asian supply chain disruptions and patent disputes. Meanwhile, the development of bioengineered solutions in the US relies on government grants, which guarantees protection from sanctions, and the metric stands at 2.25. Ownership of exclusive technology for creating living implants allows the business to maintain pricing power for its surgical services.

Professional capital evaluates the profile of Humacyte, Inc. (HUMA) through the debt-to-equity ratio, which determines the issuer's financial autonomy. The current debt-to-capitalization ratio on the balance sheet at 2.25 demonstrates the degree of dependence on creditors, while a unique patent portfolio and FDA breakthrough therapy designation ensure the asset's high investment reliability.